Naringenin Decreases Invasiveness and Metastasis by Inhibiting TGF-β-Induced Epithelial to Mesenchymal Transition in Pancreatic Cancer Cells
Open Access
- 26 December 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (12), e50956
- https://doi.org/10.1371/journal.pone.0050956
Abstract
Epithelial to mesenchymal transition (EMT) promotes cellular motility, invasiveness and metastasis during embryonic development and tumorigenesis. Transforming growth factor-β (TGF-β) signaling pathway is a key regulator of EMT. A lot of evidences suggest that this process is Smad3-dependent. Herein we showed that exposure of aspc-1 and panc-1 pancreatic cancer cells to TGF-β1 resulted in characteristic morphological alterations of EMT, and enhancement of cell motility and gemcitabine (Gem) resistance along with an up-regulation of EMT markers genes such as vimentin, N-cadherin, MMP2 and MMP9. Naringenin (Nar) down-regulated EMT markers expression in both mRNA and protein levels by inhibiting TGF-β1/Smad3 signal pathway in the pancreatic cancer cells. Consequently, Nar suppressed the cells migration and invasion and reversed their resistance to Gem.This publication has 39 references indexed in Scilit:
- Ablation of Smurf2 reveals an inhibition in TGF-β signalling through multiple mono-ubiquitination of Smad3The EMBO Journal, 2011
- A single-molecule study of the inhibition effect of Naringenin on transforming growth factor-β ligand–receptor bindingChemical Communications, 2011
- Retracted: Restoring sensitivity to oxaliplatin by a novel approach in gemcitabine‐resistant pancreatic cancer cells in vitro and in vivoInternational Journal of Cancer, 2010
- Phenolic Compounds as Selective Antineoplasic Agents against Multidrug-resistant Human Cancer CellsPlanta Medica, 2010
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Naringenin: A Potential Immunomodulator for Inhibiting Lung Fibrosis and MetastasisCancer Research, 2009
- Effects of low dose quercetin: Cancer cell‐specific inhibition of cell cycle progressionJournal of Cellular Biochemistry, 2008
- Phase I clinical trial of a TGF-β antisense-modified tumor cell vaccine in patients with advanced gliomaCancer Gene Therapy, 2006
- Development of TGF-β signalling inhibitors for cancer therapyNature Reviews Drug Discovery, 2004
- N-Cadherin Expression and Epithelial-Mesenchymal Transition in Pancreatic CarcinomaClinical Cancer Research, 2004